Gensight Biologics S.a annual return on equity
2021
2022
Gensight Biologics S.a Return on Equity (ROE) Growth & History (SIGHT)
Gensight Biologics S.a's return on equity was −7,781.69% for fiscal 2022.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | −7,781.69% | −7575.35 pp |
| 2021 | 2021-12-31 | −206.34% | — |
Gensight Biologics S.a return on equity trends
Between the periods ended 2021-12-31 and 2022-12-31, Gensight Biologics S.a's return on equity decreased from −206.34% to −7,781.69%, a change of −7575.35 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...